Actively Recruiting
PET Imaging Targeting Granzyme B Predicts Immunotherapy Efficacy in Diffuse Large B-cell Lymphoma
Led by Ruijin Hospital · Updated on 2025-01-01
150
Participants Needed
1
Research Sites
260 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study aims to investigate the predictive value of PET imaging targeting granzyme B on the outcome of patients with diffuse large B lymphoma receiving immunotherapy.
CONDITIONS
Official Title
PET Imaging Targeting Granzyme B Predicts Immunotherapy Efficacy in Diffuse Large B-cell Lymphoma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Pathologic diagnosis of DLBCL
- General condition is good with expected survival greater than six months
- Signed and dated informed consent form
You will not qualify if you...
- Presence of other malignant tumors
- Serious medical conditions deemed unsuitable by the investigator
- Pregnant or breastfeeding women, and women at risk of pregnancy
- Poor compliance
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Ruijin Hospital Affiliated to Shanghai Jiao Tong University Medical School
Shanghai, China
Actively Recruiting
Research Team
X
Xinyi Zhu
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here